Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Steyn

Showing results (121-130 of 168) with videos related to

Pageof 17
Sort By:
Neurology|February 13, 2024
Variation in Resting Metabolic Rate Affects Identification of Metabolic Change in Geographically Distinct Cohorts of Patients With ALSCory J Holdom, Mark R Janse van Mantgem, Ji He, et al.
Bioorganic & Medicinal Chemistry Letters|August 13, 2014
Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffoldPaul Galatsis, Jaclyn L Henderson, Bethany L Kormos, et al.
Cell Reports Methods|May 10, 2025
Site-specific quantification of the in vivo UFMylome reveals myosin modification in ALSRonnie Blazev, Barry M Zee, Hayley Peckham, et al.
Brain Communications|February 26, 2025
An open-label Phase 2a study to assess the safety and tolerability of trimetazidine in patients with amyotrophic lateral sclerosisRuben P A van Eijk, Frederik J Steyn, Mark R Janse van Mantgem, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 1, 2018
Hypermetabolism in ALS is associated with greater functional decline and shorter survivalFrederik J Steyn, Zara A Ioannides, Ruben P A van Eijk, et al.
Journal of Medicinal Chemistry|October 18, 2022
Imaging Leucine-Rich Repeat Kinase 2 In Vivo with <sup>18</sup>F-Labeled Positron Emission Tomography LigandZhen Chen, Jiahui Chen, Laigao Chen, et al.
Journal of Neurology|July 18, 2022
Patient perspectives on digital healthcare technology in care and clinical trials for motor neuron disease: an international surveyJochem Helleman, Barbara Johnson, Cory Holdom, et al.
Iscience|May 7, 2020
Skeletal-Muscle Metabolic Reprogramming in ALS-SOD1<sup>G93A</sup> Mice Predates Disease Onset and Is A Promising Therapeutic TargetSilvia Scaricamazza, Illari Salvatori, Giacomo Giacovazzo, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 24, 2024
Characterization of the skeletal muscle arginine methylome in health and disease reveals remodeling in amyotrophic lateral sclerosisJulian P H Wong, Ronnie Blazev, Yaan-Kit Ng, et al.
Journal of Medicinal Chemistry|October 30, 2014
Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitorJaclyn L Henderson, Bethany L Kormos, Matthew M Hayward, et al.
Pageof 17

Showing results (121-130 of 168) with videos related to

Sort By:
Pageof 17
Neurology|February 13, 2024
Variation in Resting Metabolic Rate Affects Identification of Metabolic Change in Geographically Distinct Cohorts of Patients With ALSCory J Holdom, Mark R Janse van Mantgem, Ji He, et al.
Bioorganic & Medicinal Chemistry Letters|August 13, 2014
Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffoldPaul Galatsis, Jaclyn L Henderson, Bethany L Kormos, et al.
Cell Reports Methods|May 10, 2025
Site-specific quantification of the in vivo UFMylome reveals myosin modification in ALSRonnie Blazev, Barry M Zee, Hayley Peckham, et al.
Brain Communications|February 26, 2025
An open-label Phase 2a study to assess the safety and tolerability of trimetazidine in patients with amyotrophic lateral sclerosisRuben P A van Eijk, Frederik J Steyn, Mark R Janse van Mantgem, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 1, 2018
Hypermetabolism in ALS is associated with greater functional decline and shorter survivalFrederik J Steyn, Zara A Ioannides, Ruben P A van Eijk, et al.
Journal of Medicinal Chemistry|October 18, 2022
Imaging Leucine-Rich Repeat Kinase 2 In Vivo with <sup>18</sup>F-Labeled Positron Emission Tomography LigandZhen Chen, Jiahui Chen, Laigao Chen, et al.
Journal of Neurology|July 18, 2022
Patient perspectives on digital healthcare technology in care and clinical trials for motor neuron disease: an international surveyJochem Helleman, Barbara Johnson, Cory Holdom, et al.
Iscience|May 7, 2020
Skeletal-Muscle Metabolic Reprogramming in ALS-SOD1<sup>G93A</sup> Mice Predates Disease Onset and Is A Promising Therapeutic TargetSilvia Scaricamazza, Illari Salvatori, Giacomo Giacovazzo, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 24, 2024
Characterization of the skeletal muscle arginine methylome in health and disease reveals remodeling in amyotrophic lateral sclerosisJulian P H Wong, Ronnie Blazev, Yaan-Kit Ng, et al.
Journal of Medicinal Chemistry|October 30, 2014
Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitorJaclyn L Henderson, Bethany L Kormos, Matthew M Hayward, et al.
Pageof 17